Copperwynd Financial LLC Increases Stock Position in ImmunityBio, Inc. (NASDAQ:IBRX)

Copperwynd Financial LLC grew its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 99.1% in the 4th quarter, Holdings Channel reports. The institutional investor owned 20,087 shares of the company’s stock after buying an additional 10,000 shares during the quarter. Copperwynd Financial LLC’s holdings in ImmunityBio were worth $51,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. GSA Capital Partners LLP lifted its holdings in shares of ImmunityBio by 290.3% during the 3rd quarter. GSA Capital Partners LLP now owns 107,985 shares of the company’s stock valued at $402,000 after acquiring an additional 80,318 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of ImmunityBio during the 3rd quarter valued at $253,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of ImmunityBio by 2.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,265,981 shares of the company’s stock valued at $4,709,000 after acquiring an additional 29,665 shares in the last quarter. Advantage Alpha Capital Partners LP acquired a new position in shares of ImmunityBio during the 3rd quarter valued at $257,000. Finally, Quantbot Technologies LP acquired a new position in shares of ImmunityBio during the 3rd quarter valued at $143,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on IBRX. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of ImmunityBio in a report on Thursday. D. Boral Capital reiterated a “buy” rating and issued a $30.00 price objective on shares of ImmunityBio in a report on Thursday. Finally, BTIG Research began coverage on shares of ImmunityBio in a report on Friday, January 10th. They issued a “buy” rating and a $6.00 price objective on the stock. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $12.19.

ImmunityBio Price Performance

Shares of IBRX stock opened at $2.87 on Friday. ImmunityBio, Inc. has a 12 month low of $2.28 and a 12 month high of $10.53. The firm has a market capitalization of $2.45 billion, a P/E ratio of -3.12 and a beta of 0.82. The company’s fifty day moving average price is $3.08 and its two-hundred day moving average price is $3.66.

ImmunityBio (NASDAQ:IBRX) last released its earnings results on Monday, March 3rd. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.11. The company had revenue of $7.55 million during the quarter, compared to the consensus estimate of $8.74 million. On average, sell-side analysts anticipate that ImmunityBio, Inc. will post -0.92 EPS for the current year.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.